



TIRmed Pharma raises EUR 4.3 million – preparing for clinical development of new immunomodulatory treatment for atopic dermatitis

TIRmed Pharma, a biotech company developing innovative treatments for autoimmune skin diseases, has raised EUR 4.3 million in a funding round led by Society and Society Venture Partners. The investment will support the company's transition into clinical development of its immunomodulatory treatment for atopic dermatitis – a condition with significant unmet medical need, where more effective therapies with favorable safety profiles are still lacking.



The EUR 4.3 million raised will enable completion of toxicology studies, GMP production, and initiation of the company's first Phase Ib clinical trial in patients with atopic dermatitis.

Atopic dermatitis is one of the most common skin diseases worldwide, affecting millions of people each year. It is a chronic inflammatory condition often associated with intense itching, skin irritation, and sleep disruption – with a significant negative impact on quality of life. Despite multiple treatment options available today, the majority of patients experience insufficient relief, and many existing treatments are limited by short-term efficacy or side effects. The need for new, more sustainable therapies is substantial.

TIRmed Pharma is developing a novel treatment based on an oligonucleotide applied directly to the skin, acting locally by modulating the immune system at the site of disease. This targeted, immunomodulatory mechanism of action helps reduce systemic exposure and thereby minimizes the risk of side effects – a key advantage over many current treatments.

In preclinical studies, the treatment has shown promising results, including sustained symptom relief for up to 15 months after just five applications over two weeks. The goal is to offer a more effective, long-lasting, and safer alternative for patients with atopic dermatitis – improving both treatment outcomes and overall quality of life.

“This capital injection enables us to take the decisive step into clinical development and move closer to a future where patients have access to more durable and effective treatment. The strong support from Societ and their investor network gives us both the momentum and the means to accelerate our development,” says Leo Holmgren, CEO of TIRmed Pharma.

The funding round attracted strong investor interest, underscoring both the growing need for innovation in dermatology and confidence in TIRmed Pharma’s strategy.

“TIRmed Pharma takes a clear approach to addressing a significant medical need in dermatology. We see a feasible clinical strategy, strong preclinical data, and an experienced team ready to take the next step. That makes the company a natural fit for our portfolio,” says Andreas Lindblom, Managing Partner at Societ.

The global market for atopic dermatitis treatments is currently valued at approximately USD 9.3 billion and is projected to grow by 8–10 percent annually through 2032.

For more information, please contact:

Leo Holmgren, CEO

Phone: +46 70 049 18 42

Email: leo.holmgren@tirmedpharma.com

About TIRmed Pharma

TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on Atopic Dermatitis (eczema). Despite being a common condition, current treatments often provide only symptomatic relief. The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease’s underlying mechanisms rather than just controlling symptoms. Promising preclinical results support its potential to provide long-lasting relief and reduce treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options.

TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit tirmedpharma.com and follow TIRmed on [LinkedIn](#).

Om Societ

Societ is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Societ Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. Learn more at societ.com and follow Societ on [LinkedIn](#).